How Voya’s Expanded Private Market Access in Retirement Accounts Could Shape Voya Financial (VOYA) Investors

• In early July 2026, Voya Financial, Inc. expanded private asset capabilities within its Advisor Managed Accounts program, allowing registered investment advisors to incorporate private equity, private credit and private real estate into professionally managed retirement portfolios for plan participants.
• This move further opens historically less accessible private markets to workplace savers through education-led, professionally managed solutions that aim to broaden portfolio diversification within employer-sponsored plans.
• We’ll now examine how this broadened access to private market investments through advisor managed accounts could influence Voya Financial’s existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Voya Financial Investment Narrative Recap

To own Voya Financial, you generally need to believe in steady fee-based growth from workplace retirement, wealth, and benefits, supported by disciplined capital returns. The AMA private assets expansion reinforces Voya’s push into higher-value advice and investment solutions, but it does not materially change the near term focus on integrating acquisitions and managing fee pressure and regulatory risk around alternative investments.

The July 2026 AMA announcement ties directly back to Voya’s 2025 partnership with Blue Owl Capital, which began building private market collective investment trusts for defined contribution plans. Together, these efforts sit alongside Voya’s broader product and digital enhancements, such as MyCompass Blend and the SAVVI retirement guidance tools, and could interact with the key catalyst of rising demand for alternative and tailored solutions within workplace retirement plans.

Yet, while broader private-market access can look appealing, investors should also be aware that...

Read the full narrative on Voya Financial (it's free!)

Voya Financial's narrative projects $8.4 billion revenue and $1.1 billion earnings by 2029. This implies essentially flat yearly revenue growth and a roughly $0.5 billion earnings increase from $639.0 million today.

Uncover how Voya Financial's forecasts yield a $98.50 fair value, in line with its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming earnings could reach about US$1.1 billion by 2029, and see this kind of private markets expansion as potentially reinforcing that view, while others worry that if long term demand for private credit and similar products softens, Voya’s investment management growth could look very different from those bullish expectations.

Explore 2 other fair value estimates on Voya Financial - why the stock might be worth as much as 48% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Voya Financial research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Voya Financial research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Voya Financial's overall financial health at a glance.

Want Some Alternatives?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com